Challenges in idiopathic pulmonary fibrosis trials: The point on end-points

European Respiratory Review

Volumn 20, Issue 121, 2011, Pages 195-200

  Albera, C ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

6 min walk test; End points; Forced vital capacity; Idiopathic pulmonary fibrosis; Idiopathic pulmonary fibrosis trials

Indexed keywords

PIRFENIDONE; PLACEBO;

6 MINUTE WALK TEST; DRUG EFFICACY; EXERCISE TEST; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; OUTCOME ASSESSMENT; PROGNOSIS; RELIABILITY; REVIEW; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; VALIDITY;

CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 80052532595     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00001711     Document Type: Review

References (42)

1. du Bois RM, Albera C, Bradford WZ. Predictors of mortality in patients with idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med 2009; 179: A1114.
2. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
3. De Vries J, Kessels BL, Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur Respir J 2001; 17: 954-961.
4. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
5. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142: 963-967.
6. Albera C, du Bois RM, Bradford WZ. Prognostic significance of surgical lung biopsy (SLB) in a well-characterized cohort of patients with idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med 2010; 181: A2971.
7. King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-c1b for idiopathic pulmonary fibrosis. Chest 2005; 127: 171-177.
8. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebocontrolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-1047.
9. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon c-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-133.
10. du Bois RM. Is idiopathic pulmonary fibrosis now treatable? Am J Respir Crit Care Med 2005; 171: 939-940.
11. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet 2011; 377: 1760-1769.
12. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
13. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010; 181: 604-610.
14. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon c-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-228.
15. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebocontrolled trial. Am J Respir Crit Care Med 2008; 178: 948-955.
16. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
17. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-1482.
18. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
19. Karimi-Shah BA. Pulmonary-Allergy Drugs Advisory Committee Meeting. Pirfenidone capsules NDA 22-535, S-000. U.S. Food and Drug Administration. www.fda.gov/downloads/Advisory Committees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM206398.pdf
20. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the sixminute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
21. Eaton T, Young P, Milne D, et al. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171: 1150-1157.
22. Snow JL, Kawut SM. Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy. Clin Chest Med 2007; 28: 75-89, viii.
23. du Bois RM, Weycker D, Albera C, et al. Six minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183: 1231-1237.
24. du Bois RM, Albera C, Bradford WZ, et al. Percent predicted forced vital capacity (FVC) is a reliable valid and responsive measure of clinical status in patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2010; 36: Suppl. 54, 646s.
25. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-415.
26. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168: 531-537.
27. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-542.
28. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543-548.
29. Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171: 639-644.
30. Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 1084-1090.
31. Caminati A, Bianchi A, Cassandro R, et al. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 2009; 103: 117-123.
32. Lederer DJ, Arcasoy SM, Wilt JS, et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 659-664.
33. Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005; 172: 488-493.
34. Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003; 58: 143-148.
35. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; [Epub ahead of print DOI:10.1164/rccm.201011-1790OC].
36. Valeyre D, Albera C, du Bois RM. 6 minute walk distance (6MWD) and forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF): similar pattern of pirfenidone response. Am J Respir Crit Care Med 2010; 181: A6026.
37. International Conference on Harmonisation of Technical Requirements for Registaration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Statistical Principals For Clinical Trials E9. Current step 4 version. February 5, 1998. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf
38. Cannon CP. Clinical perspectives on the use of composite endpoints. Control Clin Trials 1997; 18: 517-529.
39. The European Agency for the Evaluation of Medicinal Products. Evaluation of Medicines for Human Use. Committee for Proprietary Medicinal Products (CPMP). Points to Consider on Multiplicity Issues in Clinical Trials. September 19, 2002. www.tga.gov.au/docs/pdf/euguide/ewp/090899en.pdf
40. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-1234.
41. Mok TS, Wu YL, Thongprasert S, et al. Gefitinibor carboplatin-paclitaxel in pulmonary adenocarcinoma. NEngl JMed 2009; 361: 947-957.
42. Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496-504.